{'fraction_non_alphanumeric': 0.04177109440267335, 'fraction_numerical': 0.029239766081871343, 'mean_word_length': 4.872549019607843, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
GROWTH AND ENDOCRINE ABNORMALITIES IN PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS

It is known that patients with Langerhans Cell Histiocytosis (LCH) are accompanied by a variety of hypothalamic-pituitary dysfunction (HPD). To test the hypothesis that the endocrine abnormalities associated with LCH are related to the final height, we studied 45 patients with LCH. Twenty patients (5 boys and 15 girls) had been followed until they reached the final height. Observed clinical manifestations due to HPD were: diabetes insipidus in 11 patients, growth hormone deficiency in 6 patients, precocious puberty in 3 patients, ACTH deficiency in 6 patients and TSH deficiency in 2 patients. The mean SD score of body height of patients was not different from normal control at the onset of LCH. However, the mean SD score of the final height of the patients with LCH was significntly lower than normal control (−1.80±1.81; mean±SD). The mean SD score of the final height of the patients with HPD (n=13) was significantly lower than the patients without HPD (n=7) (−2.50±1.60 vs −0.59±1.38; mean±SD, P<0.05). We conclude that the endocrine abnormalities associated with LCH are related to the final height.